OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country… Read on
A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer… Read on
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer… Read on
(December 30, 2013) The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women… Read on
(December 20, 2013) Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival… Read on
A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable… Read on
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro… Read on
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the… Read on
George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has… Read on
New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer… Read on
